BioCentury | Jan 5, 2021
Finance

Immuneering, Terns, Ikena raise crossover rounds as IPO queue stands to grow again

...has a clinical development team based in Shanghai.Ikena Oncology...
...Funds as the leader. Previously known as Kyn...
BioCentury | Aug 19, 2020
Management Tracks

Rao to head Sobi R&D; plus new CMOs for Ikena, Agile, Nordic Nanovector and more

...medical head, immunology and specialty medicine franchise at GlaxoSmithKline plc (LSE:GSK; NYSE:GSK). Zdravkovic is pursuing new opportunities. Ikena Oncology...
...company from Cellectis S.A. (Euronext:ALCLS; NASDAQ:CLLS), where he was EVP of technical operations. Robin Sawka Swedish Orphan Biovitrum AB Ikena Oncology Agile...
BioCentury | Dec 6, 2019
Targets & Mechanisms

Emerging immuno-oncology mechanisms at ASH 2019

...2018 to 2019 include ARG1, which dropped from eight mentions to one this year, and KYN...
BioCentury | May 8, 2019
Company News

Management tracks: Immunocore, Kyn, Engitix

...Berman as head of R&D in September 2018 and Bahija Jallal as CEO in January. Kyn...
...Johnson & Johnson (NYSE:JNJ) in 2010. BioCentury Staff Algiax Pharmaceuticals GmbH Aquestive Therapeutics Inc. CDx Diagnostics CohBar Inc. Engitix Ltd. Immunic Inc. Immunocore Ltd. Kyn...
BioCentury | Feb 4, 2019
Company News

Management tracks: PhRMA, Amgen, Apellis

...was VP of quality solids Americas and special technologies at Novartis AG (NYSE:NVS; SIX:NOVN). Immuno-oncology Kyn...
BioCentury | Feb 1, 2019
Company News

Celgene gains option for Triphase's epigenetic cancer therapy

...is at least its third option deal since, with the bellwether recently announcing deals with Kyn...
...Cambridge, Mass.) (see "Bristol-Myers' Next Phoenix Act?" and "Celgene Bolsters Immuno-Metabolism, Immune Cell Toolbox with Kyn...
BioCentury | Jan 29, 2019
Company News

Celgene gains option for Triphase's epigenetic cancer therapy

...is at least its third option deal since, with the bellwether recently announcing deals with Kyn...
...Cambridge, Mass.) (see "Bristol-Myers' Next Phoenix Act?" and "Celgene Bolsters Immuno-Metabolism, Immune Cell Toolbox with Kyn...
BioCentury | Jan 25, 2019
Company News

Celgene bolsters immuno-metabolism, immune cell toolbox with Kyn, Obsidian deals

...Partnerships with Boston area biotechs Kyn Therapeutics Inc. and Obsidian Therapeutics Inc. announced on Jan. 18...
...billion in a cash and stock deal (see "Bristol-Myers' Next Phoenix Act?" ). Through the Kyn...
...Inc., Cambridge, Mass. Business: Cancer Karen Tkach Tuzman AhR Bristol-Myers Squibb Co. Celgene Corp. Kyn Therapeutics Inc. Obsidian Therapeutics Inc. Interleukin-12 (IL-12) Kynurenine (KYN) CD40L immuno-metabolism...
BioCentury | Jan 19, 2019
Company News

Celgene bolsters immuno-metabolism, immune cell toolbox with Kyn, Obsidian deals

...Partnerships with Boston area biotechs Kyn Therapeutics Inc. and Obsidian Therapeutics Inc. announced late this week...
...billion in a cash and stock deal (see "Bristol-Myers' Next Phoenix Act?" ). Through the Kyn...
...enzyme that degrades immunosuppressive metabolite kynurenine, and the other an antagonist of kynurenine receptor AHR. Kyn...
BioCentury | Nov 30, 2018
Targets & Mechanisms

Revving up metabolism at ASH 2018

...hydrocarbon receptor (AHR) 7 Indoleamine 2,3-dioxygenase (IDO; INDO) 7 Indoleamine 2,3-dioxygenase 1 (IDO1) 7 Kynurenine (KYN...
Items per page:
1 - 10 of 21
BioCentury | Jan 5, 2021
Finance

Immuneering, Terns, Ikena raise crossover rounds as IPO queue stands to grow again

...has a clinical development team based in Shanghai.Ikena Oncology...
...Funds as the leader. Previously known as Kyn...
BioCentury | Aug 19, 2020
Management Tracks

Rao to head Sobi R&D; plus new CMOs for Ikena, Agile, Nordic Nanovector and more

...medical head, immunology and specialty medicine franchise at GlaxoSmithKline plc (LSE:GSK; NYSE:GSK). Zdravkovic is pursuing new opportunities. Ikena Oncology...
...company from Cellectis S.A. (Euronext:ALCLS; NASDAQ:CLLS), where he was EVP of technical operations. Robin Sawka Swedish Orphan Biovitrum AB Ikena Oncology Agile...
BioCentury | Dec 6, 2019
Targets & Mechanisms

Emerging immuno-oncology mechanisms at ASH 2019

...2018 to 2019 include ARG1, which dropped from eight mentions to one this year, and KYN...
BioCentury | May 8, 2019
Company News

Management tracks: Immunocore, Kyn, Engitix

...Berman as head of R&D in September 2018 and Bahija Jallal as CEO in January. Kyn...
...Johnson & Johnson (NYSE:JNJ) in 2010. BioCentury Staff Algiax Pharmaceuticals GmbH Aquestive Therapeutics Inc. CDx Diagnostics CohBar Inc. Engitix Ltd. Immunic Inc. Immunocore Ltd. Kyn...
BioCentury | Feb 4, 2019
Company News

Management tracks: PhRMA, Amgen, Apellis

...was VP of quality solids Americas and special technologies at Novartis AG (NYSE:NVS; SIX:NOVN). Immuno-oncology Kyn...
BioCentury | Feb 1, 2019
Company News

Celgene gains option for Triphase's epigenetic cancer therapy

...is at least its third option deal since, with the bellwether recently announcing deals with Kyn...
...Cambridge, Mass.) (see "Bristol-Myers' Next Phoenix Act?" and "Celgene Bolsters Immuno-Metabolism, Immune Cell Toolbox with Kyn...
BioCentury | Jan 29, 2019
Company News

Celgene gains option for Triphase's epigenetic cancer therapy

...is at least its third option deal since, with the bellwether recently announcing deals with Kyn...
...Cambridge, Mass.) (see "Bristol-Myers' Next Phoenix Act?" and "Celgene Bolsters Immuno-Metabolism, Immune Cell Toolbox with Kyn...
BioCentury | Jan 25, 2019
Company News

Celgene bolsters immuno-metabolism, immune cell toolbox with Kyn, Obsidian deals

...Partnerships with Boston area biotechs Kyn Therapeutics Inc. and Obsidian Therapeutics Inc. announced on Jan. 18...
...billion in a cash and stock deal (see "Bristol-Myers' Next Phoenix Act?" ). Through the Kyn...
...Inc., Cambridge, Mass. Business: Cancer Karen Tkach Tuzman AhR Bristol-Myers Squibb Co. Celgene Corp. Kyn Therapeutics Inc. Obsidian Therapeutics Inc. Interleukin-12 (IL-12) Kynurenine (KYN) CD40L immuno-metabolism...
BioCentury | Jan 19, 2019
Company News

Celgene bolsters immuno-metabolism, immune cell toolbox with Kyn, Obsidian deals

...Partnerships with Boston area biotechs Kyn Therapeutics Inc. and Obsidian Therapeutics Inc. announced late this week...
...billion in a cash and stock deal (see "Bristol-Myers' Next Phoenix Act?" ). Through the Kyn...
...enzyme that degrades immunosuppressive metabolite kynurenine, and the other an antagonist of kynurenine receptor AHR. Kyn...
BioCentury | Nov 30, 2018
Targets & Mechanisms

Revving up metabolism at ASH 2018

...hydrocarbon receptor (AHR) 7 Indoleamine 2,3-dioxygenase (IDO; INDO) 7 Indoleamine 2,3-dioxygenase 1 (IDO1) 7 Kynurenine (KYN...
Items per page:
1 - 10 of 21